Skip to Content

'
Felipe Samaniego

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Associate Professor, Department of Immunology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
7455 Fannin St
Unit 903
Houston, TX 77054
Phone: 713-563-3421
Fax: 713-563-3424

Education & Training

Degree-Granting Education

1983 Harvard Medical School, Boston, MA, MD, Medicine
1983 Harvard School of Public Health, Boston, MA, MPH, Medicine
1978 New Mexico State University, Las Cruces, NM, BS, Biology

Postgraduate Training

1/1990-1995 RESEARCH FELLOW, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, NIH, Bethesda, MD
1/1986-1990 CLINICAL FELLOW, Hematology-Oncology, Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
1/1984-1986 RESIDENT, University of Colorado Health Sciences Center, Denver, CO
1/1983-1984 INTERN, University of Colorado Health Sciences Center, Denver, CO

Board Certifications

1/1989 American Board of Medical Oncology
1/1986 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/2003-2006
Assistant Professor, Human Virology, Institute of Human Virology, University of Maryland Medical Center, Maryland, MD, 1/1996-1/1999

Honors and Awards

2002 AACR-MICR Council Member, AACR-MICR
1989 Daland Fellowship, Alternate Fellow
1989 Robert Wood Johnson Foundation Fellow

Selected Publications

Peer-Reviewed Original Research Articles
1. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 6/2009. e-Pub 2/23/2009. PMID: 19237479.
2. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 4/2009. e-Pub 1/15/2009. PMID: 19150940.
3. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst 101(6):399-411, 3/18/2009. e-Pub 3/10/2009. PMCID: PMC2720696.
4. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Mederiros LJ, Fayad L, Samaniego F, Alousi A, Anderlinie P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Chamlin RE. 8-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood. e-Pub 2008.
5. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2008.
6. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaiego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 3:553-9, 2008.
7. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109(5):2174-82, 2007. PMID: 17090655.
8. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas F. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 2005. PMID: 16145068.
9. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105(12):4573-5, 2005. PMID: 15741224.
10. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2005. PMID: 15613697.
11. Duvic M, Hodak E, Talpur R, Samaniego F, Jones D. Complete Response of a Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphoma to Denileukin Diftitox. Case Studies in Lymphoma 3(1):3-6, 2004.
12. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100(6):1186-9, 2004. PMID: 15022285.
13. Prakash O, Tang ZY, Peng X, Coleman R, Gill J, Farr G, Samaniego F. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J Natl Cancer Inst 94(12):926-35, 2002. PMID: 12072546.
14. Samaniego F, Young D, Grimes C, Prospero V, Christofidou-Solomidou M, DeLisser HM, Prakash O, Sahin AA, Wang S. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts. Cell Growth Differ 13(8):387-95, 2002. PMID: 12193477.
15. Samaniego F, Pati S, Karp JE, Prakash O, Bose D. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? J Natl Cancer Inst Monogr(28):15-23, 2001. PMID: 11158202.
16. Prakash O, Tang ZY, He YE, Ali MS, Coleman R, Gill J, Farr G, Samaniego F. Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 tat-expressing transgenic mice. J Natl Cancer Inst 92(9):721-8, 2000. PMID: 10793108.
17. Samaniego F, Bryant JL, Liu N, Karp JE, Sabichi AL, Thierry A, Lunardi-Iskandar Y, Gallo RC. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin. J Natl Cancer Inst 91(2):135-43, 1999. PMID: 9923854.
18. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, Sturzl M, Ensoli B. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94(2):663-72, 1999. PMID: 10397733.
19. Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, Sonnabend JA, Pintus A, Gallo RC, Ensoli B. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152(6):1433-43, 1998. PMID: 9626048.
20. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids 11(12):1421-31, 10/1997. PMID: 9342064.
21. Samaniego F, Markham PD, Gendelman R, Gallo RC, Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 158(4):1887-94, 1997. PMID: 9029130.
22. Samaniego F, Wheeler D. The Tumorigenesis of Kaposi’s sarcoma. Scientific American (Investigacion Y Ciencia) 249:37-38, 1996.
23. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 154(7):3582-92, 4/1995. PMID: 7897237.
24. Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2. Structure, function, and post-translational regulation. J Biol Chem 269(49):30904-10, 1994. PMID: 7983023.
25. Ladanyi M, Samaniego F, Reuter VE, Motzer RJ, Jhanwar SC, Bosl GJ, Chaganti RS. Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors. J Natl Cancer Inst 82(3):221-7, 1990. PMID: 2153216.
26. Samaniego F, Rodriguez E, Houldsworth J, Murty VV, Ladanyi M, Lele KP, Chen QG, Dmitrovsky E, Geller NL, Reuter V, et al. Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. Genes Chromosomes Cancer 1(4):289-300, 1990. PMID: 2177638.
27. Samaniego F, Newman LS. Migratory anisocoria--a novel clinical entity. Am Rev Respir Dis 134(4):844, 1986. PMID: 2945505.
28. Samaniego FC, Berry F, Dice JF. Selective depletion of small basic non-glycosylated proteins in diabetes. Biochem J 198(1):149-57, 1981. PMID: 7325991.

Abstracts
1. Maeng H, Berkova Z, Wang S, Wang S, Prakash O, Yi Q, Samaniego F. Human herpesvirus 8 protein K1 interferes with Fas-mediated apoptosis and stimulates clonal growth and lymphoid hyperplasia. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research(A2712), 2008.

Last updated: 9/9/2009